Increasing demand for antibodies in therapeutic applications is fostering the growth of the antibodies market

 

Antibodies Market

Antibodies also referred to as immunoglobulin, are basically a large, polysaccharide Y-shape protein that is used by your body to identify and destroy foreign objects like viruses and pathogens. The antibody recognizes an external molecule of the pathogen, known as antigens. The antibodies release substances into the lymphatic fluid where they interact with the infected cells. These release substances to assist in destroying the infected cells and preventing infection from recurring.

The growing demand for antibodies in therapeutic applications is propelling the growth of the antibodies market. The increasing economic burden of cancers and other chronic diseases is also supporting the growth of the market. According to the International Agency for Research on Cancer, in 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Therapeutic monoclonal antibodies are majorly used across oncology, neurobiology, autoimmunology, and cardiology area. Thus growing prevalence of various chronic diseases coupled with the increasing advancement in drug development is further projected to boost the growth of the antibodies market.

North America is projected to gain significant growth over the forecast period and this is attributed to the growing number of research and development programs for exploring the properties of therapeutic antibodies. For instance, in September 2020, Eli Lilly has reported the interim results from a placebo-controlled trial of one such compound, cloned in quantity from an antibody captured from the blood of a patient who recovered from COVID-19. In June, the company began a trial delivering either a placebo or one of three doses of the antibody, called LY-CoV555, to 452 patients. 

Key Developments:

1.      In December 2019, Mylan and Biocon announced the launch of a new product under the monoclonal antibody therapy category. The company introduced ‘Ogivri,’ a product that is a biosimilar of trastuzumab

2.      In September 2020, Roche announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA)

3.      In April 2020, Abbott announced the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG that identifies if a person has had the novel coronavirus (COVID-19)

4.      In May 2020, French diagnostics specialist BioMérieux announced the launch of a new product that aims to detect within 30 minutes the presence of antibodies in those exposed to the coronavirus.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region

The market for ureteral stents would benefit from the rising prevalence of urological diseases